0001193125-26-191513
SEC filingProfitability surged in Q1 2026 as operating margin expansion and lower R&D costs offset modest revenue growth, resulting in a 72% increase in net income.
Operating income surged 26% to $652 million, driving operating margin to 16.4%. This expansion was supported by a 5% increase in gross profit to $2.0 billion, yielding a gross margin of 49.5%. The improvement in profitability metrics reflects successful cost management and operational efficiency. Management noted that R&D expenses decreased compared to the prior year, primarily due to a reduction in the generics pipeline and late-stage innovative pipeline in neuroscience, partially offset by increased investment in immunology projects. This strategic reallocation of R&D resources aligns with the company's focus on high-value therapeutic areas.
Net income rose 72% to $369 million, or $0.31 per diluted share, representing a significant improvement from the prior year's $214 million. This bottom-line expansion was driven by the higher operating income and disciplined expense management. The company continues to execute on its "Accelerate Growth" strategy, focusing on growing its innovative portfolio and modernizing operations to drive efficiency. Management emphasized aligning capital allocation to invest in activities expected to generate the highest value.